291 related articles for article (PubMed ID: 19645630)
1. Engineered adenovirus serotypes for overcoming anti-vector immunity.
Dharmapuri S; Peruzzi D; Aurisicchio L
Expert Opin Biol Ther; 2009 Oct; 9(10):1279-87. PubMed ID: 19645630
[TBL] [Abstract][Full Text] [Related]
2. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.
Seregin SS; Amalfitano A
Expert Opin Biol Ther; 2009 Dec; 9(12):1521-31. PubMed ID: 19780714
[TBL] [Abstract][Full Text] [Related]
3. Innate immune response induced by gene delivery vectors.
Sakurai H; Kawabata K; Sakurai F; Nakagawa S; Mizuguchi H
Int J Pharm; 2008 Apr; 354(1-2):9-15. PubMed ID: 17640834
[TBL] [Abstract][Full Text] [Related]
4. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
Varnavski AN; Calcedo R; Bove M; Gao G; Wilson JM
Gene Ther; 2005 Mar; 12(5):427-36. PubMed ID: 15647774
[TBL] [Abstract][Full Text] [Related]
6. [Adenovirus vectors and their clinical application in gene therapy].
Adám E; Nász I
Orv Hetil; 2001 Sep; 142(38):2061-70. PubMed ID: 11697063
[TBL] [Abstract][Full Text] [Related]
7. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.
Schagen FH; Ossevoort M; Toes RE; Hoeben RC
Crit Rev Oncol Hematol; 2004 Apr; 50(1):51-70. PubMed ID: 15094159
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
Bessis N; GarciaCozar FJ; Boissier MC
Gene Ther; 2004 Oct; 11 Suppl 1():S10-7. PubMed ID: 15454952
[TBL] [Abstract][Full Text] [Related]
9. Development and application of adenoviral vectors for gene therapy of cancer.
Zhang WW
Cancer Gene Ther; 1999; 6(2):113-38. PubMed ID: 10195879
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus vector-mediated gene transfer into stem cells.
Kawabata K; Sakurai F; Koizumi N; Hayakawa T; Mizuguchi H
Mol Pharm; 2006; 3(2):95-103. PubMed ID: 16579638
[TBL] [Abstract][Full Text] [Related]
11. Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities.
Amalfitano A
Curr Opin Mol Ther; 2003 Aug; 5(4):362-6. PubMed ID: 14513678
[TBL] [Abstract][Full Text] [Related]
12. Development of PEGylated adenovirus vector with targeting ligand.
Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
[TBL] [Abstract][Full Text] [Related]
13. Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent.
Appledorn DM; Kiang A; McBride A; Jiang H; Seregin S; Scott JM; Stringer R; Kousa Y; Hoban M; Frank MM; Amalfitano A
Gene Ther; 2008 Jun; 15(12):885-901. PubMed ID: 18288208
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effects of sugar-modified cationic liposome/NF-kappaB decoy complexes on adenovirus vector-induced innate immune responses.
Huang H; Sakurai F; Higuchi Y; Kawakami S; Hashida M; Kawabata K; Mizuguchi H
J Control Release; 2009 Jan; 133(2):139-45. PubMed ID: 18977256
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy.
Tosch C; Geist M; Ledoux C; Ziller-Remi C; Paul S; Erbs P; Corvaia N; Von Hoegen P; Balloul JM; Haegel H
Cancer Gene Ther; 2009 Apr; 16(4):310-9. PubMed ID: 18949016
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy with poxvirus vectors.
Moroziewicz D; Kaufman HL
Curr Opin Mol Ther; 2005 Aug; 7(4):317-25. PubMed ID: 16121697
[TBL] [Abstract][Full Text] [Related]
17. Recombinant adenoviruses as vaccines.
Randrianarison-Jewtoukoff V; Perricaudet M
Biologicals; 1995 Jun; 23(2):145-57. PubMed ID: 7546657
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of the inflammatory response to adenovirus vectors.
Liu Q; Muruve DA
Gene Ther; 2003 Jun; 10(11):935-40. PubMed ID: 12756413
[TBL] [Abstract][Full Text] [Related]
19. New serotypes of adenoviral vectors.
Stone D; Lieber A
Curr Opin Mol Ther; 2006 Oct; 8(5):423-31. PubMed ID: 17078384
[TBL] [Abstract][Full Text] [Related]
20. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.
Urosevic M; Fujii K; Calmels B; Laine E; Kobert N; Acres B; Dummer R
J Clin Invest; 2007 Oct; 117(10):2834-46. PubMed ID: 17823660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
